-
公开(公告)号:US20190135886A1
公开(公告)日:2019-05-09
申请号:US16121745
申请日:2018-09-05
申请人: Zealand Pharma A/S
发明人: Rasmus JUST , Ditte RIBER , Anne Pernille Tofteng SHELTON , Torben ØSTERLUND , Kate HANSEN , Lene JESSEN
IPC分类号: C07K14/575 , C07K14/605
摘要: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
-
公开(公告)号:US20150299281A1
公开(公告)日:2015-10-22
申请号:US14398260
申请日:2013-05-03
申请人: Zealand Pharma A/S/
发明人: Rasmus JUST , Ditte RIBER , Anne Pernille Tofteng SHELTON , Torben ØSTERLUND , Kate HANSEN , Lene JESSEN
IPC分类号: C07K14/575
CPC分类号: C07K14/575 , A61K38/00 , C07K14/605
摘要: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
摘要翻译: 本发明涉及与野生型GIP相比包含一个或多个取代并且其具有改变的,优选增加的GLP-1活性的性质的截短的GIP类似物,例如, 如在体外功效测定中评估的。 本发明提供GIP-GLP-1双重激动剂化合物和相关方法。
-
公开(公告)号:US20160280754A1
公开(公告)日:2016-09-29
申请号:US15034778
申请日:2014-11-06
申请人: Zealand Pharma A/S
IPC分类号: C07K14/645
CPC分类号: C07K14/645 , A61K38/00 , C07K14/605
摘要: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
摘要翻译: 本发明涉及具有双重GIP和GLP-1活性的酰化GIP类似物及其在治疗代谢紊乱中的用途。
-
公开(公告)号:US20210363213A1
公开(公告)日:2021-11-25
申请号:US17388328
申请日:2021-07-29
申请人: Zealand Pharma A/S
发明人: Rasmus JUST , Ditte RIBER , Anne Pernille Tofteng SHELTON , Torben ØSTERLUND , Kate HANSEN , Lene JESSEN
IPC分类号: C07K14/605
摘要: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
-
公开(公告)号:US20190270789A1
公开(公告)日:2019-09-05
申请号:US16151603
申请日:2018-10-04
申请人: Zealand Pharma A/S
发明人: Rasmus JUST , Ditte RIBER , Anne Pernille Tofteng SHELTON , Torben ØSTERLUND , Kate HANSEN , Lene JESSEN
IPC分类号: C07K14/605
摘要: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
-
公开(公告)号:US20190218270A1
公开(公告)日:2019-07-18
申请号:US16112926
申请日:2018-08-27
申请人: Zealand Pharma A/S
IPC分类号: C07K14/645 , C07K14/605
CPC分类号: C07K14/645 , A61K38/00 , C07K14/605
摘要: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
-
7.
公开(公告)号:US20160257729A1
公开(公告)日:2016-09-08
申请号:US15034784
申请日:2014-11-06
申请人: ZEALAND PHARMA A/S
发明人: Rasmus JUST , Ditte RIBER , Anne Pernille Tofteng SHELTON , Torbenä ØSTERLUND , Kate HANSEN , Lene JESSEN
IPC分类号: C07K14/605
CPC分类号: C07K14/605 , A61K38/00
摘要: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
摘要翻译: 本发明涉及在胰高血糖素,GIP和GLP-1受体上具有激动剂活性的化合物及其在治疗代谢紊乱中的用途。
-
-
-
-
-
-